Celebrex Likely To Get Label Change Saying CV Risk Is Comparable To Ibuprofen, Naproxen

Despite concerns about difference in dosages and study discontinuation rates, US FDA advisory committee concludes that Pfizer's study demonstrated similar CV risk among the three NSAIDs.